Alpha Tau Medical Ltd.
NASDAQ:DRTSBiotechnology
+$0.04 today
- Market cap
- $1.11B
- Beta
- 1.20
- P/E (TTM)
- -15.2
- EPS (TTM)
- -$0.63
Volume 0.64M
Average 0.69M
DRTS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Alpha Tau Medical Ltd.NASDAQ: DRTS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$13.31M, compared with -$9.31M a year earlier. Trailing-twelve-month EBITDA was -$44.93M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -35.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.31M-18.4% QoQ
- Last fiscal yearDec 2025
- -$41.06M-35.5% YoY
- LTMMar 2026
- -$44.93M-42.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -43.0% | +100.0% | +143.0 pp |
| 1 year | -35.5% | +100.0% | +135.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (41.06M) USD
- Year-over-year change
- -35.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.06M) | -35.5% |
| FY2024 | 2024-12-31 | (30.3M) | -8.1% |
| FY2023 | 2023-12-31 | (28.03M) | +14.4% |
| FY2022 | 2022-12-31 | (32.74M) | -147.8% |
| FY2021 | 2021-12-31 | (13.22M) | — |
EBITDA vs competitors
How DRTS compares with its peers on the latest reported figures
- DRTS's LTM Mar 2026 EBITDA of -$44.93M is the highest of the 3 companies compared; the peer median is -$86.02M.
- Its year-over-year change of -42.6% is the 2nd highest of 3, against a peer median of -38.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$44.93M | -42.6% | — | — | |
| FY2025 | -$61.4M | -44.8% | — | 945.1% | |
| LTM Mar 2026 | -$110.64M | -31.7% | — | 17902.8% | |
| Peer median (excluding DRTS) | -$86.02M | -38.3% | — | 9423.9% | |
Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 776K | 979K | 1.07M | 1.1M | 1.23M |
| Gross Profit | (776K) | (979K) | (1.07M) | (1.1M) | (1.23M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11.45M | 20.89M | 26.42M | 27.02M | 30.83M |
| Selling, General & Admin | 2.34M | 11.25M | 9.26M | 7.92M | 10.22M |
| Operating Expenses | 13.79M | 32.14M | 34.61M | 34.94M | 41.06M |
| Depreciation & Amortization | 776K | 979K | 1.07M | 1.1M | 1.23M |
| EBITDA | (13.22M) | (32.74M) | (28.03M) | (30.3M) | (41.06M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.79M) | (32.14M) | 35.68M | (36.04M) | (42.29M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 211K | 1.79M | 4.76M | 4.28M | 3.84M |
| Interest Expense | 13.27M | 1.77M | 39K | 344K | 419K |
| Other Income / Expenses | (13.47M) | (1.61M) | 6.54M | 4.3M | (218K) |
| Income Before Tax | (27.26M) | (33.74M) | (29.14M) | (31.74M) | (42.51M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 7K | 20K | 16K | 6K | 121K |
| Net Income | (27.27M) | (33.76M) | (29.16M) | (31.75M) | (42.63M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.67) | (0.53) | (0.42) | (0.45) | (0.53) |
| EPS (Diluted) | (0.67) | (0.53) | (0.42) | (0.45) | (0.53) |
| Weighted Avg Shares | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
| Weighted Avg Shares (Diluted) | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
Alpha Tau Medical Ltd.
NASDAQ:DRTS
Intrinsic Alpha fair value
Locked
Current Price
$12.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.